Patents by Inventor Qiaoe Wei

Qiaoe Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FULLY HUMAN ANTIBODY TARGETING GPRC5D AND CHIMERIC ANTIGEN RECEPTOR (CAR) AND USE THEREOF
    Publication number: 20250049852
    Abstract: A fully human antibody targeting GPRC5D and a chimeric antigen receptor (CAR) comprising the fully human antibody. A host cell expressing the CAR, such as a CAR-T cell. A use of the fully human antibody, the CAR, and the CAR-T cell in treatment of tumors (such as multiple myeloma).
    Type: Application
    Filed: December 21, 2022
    Publication date: February 13, 2025
    Inventors: Taochao TAN, Qian LUO, Zhenyu DAI, Qiaoe WEI, Ya ZHAO, Yanying ZHANG, Jianwei LIU, Xiangyin JIA, Qianqian ZHANG, Meng XIE
  • CD5-TARGETING FULLY HUMANIZED ANTIBODY
    Publication number: 20240092925
    Abstract: Provided is a CD5-targeting fully human antibody or an antigen-binding fragment thereof, which specifically binds to CD5 with a high affinity, has a lower immunogenicity compared to heterologous antibodies, and has a good application potential in the development of antibody drugs, cell therapy drugs, detection reagents and the like.
    Type: Application
    Filed: January 12, 2022
    Publication date: March 21, 2024
    Applicant: Nanjing IASO Biotechnology Co., Ltd.
    Inventors: Taochao Tan, Qiaoe Wei, Xiangyin Jia, Jiayue Tan, Meng Xie, Zhenyu Dai
  • FULLY HUMAN SINGLE-DOMAIN TANDEM CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING CD5, AND USE THEREOF
    Publication number: 20240050568
    Abstract: Provided is a fully human single-domain tandem chimeric antigen receptor (CAR) capable of specifically binding to a CD5 protein, which comprises a CD5 binding domain, a transmembrane domain, a co-stimulatory domain and an intracellular signaling domain. Also provided are engineered immune effector cells, such as T cells, comprising the chimeric antigen receptor, and use of the CAR and the engineered immune effector cells in the treatment of diseases or conditions associated with the expression of CD5.
    Type: Application
    Filed: January 12, 2022
    Publication date: February 15, 2024
    Applicant: Nanjing IASO Biotechnology Co., Ltd.
    Inventors: Taochao Tan, Zhenyu Dai, Jianfeng Zhou, Ya Zhao, Qiaoe Wei, Xiangyin Jia, Jianwei Liu
  • FULLY HUMAN ANTIBODY TARGETING CD5, AND FULLY HUMAN CHIMERIC ANTIGEN RECEPTOR (CAR) AND APPLICATION THEREOF
    Publication number: 20240002505
    Abstract: The present application provides an anti-CD5 antibody. The present application further provides a chimeric antigen receptor (CAR) that specifically binds to a CD5 protein, which comprises a CD5 binding domain, a transmembrane domain, a co-stimulatory domain and an intracellular signaling domain. Further provided are engineered immune effector cells (such as T-cells) comprising the chimeric antigen receptor. The present application further provides use of the CAR and the engineered immune effector cells in the treatment of diseases or conditions associated with the expression of CD5.
    Type: Application
    Filed: November 1, 2021
    Publication date: January 4, 2024
    Applicant: Nanjing IASO Biotechnology Co., Ltd.
    Inventors: Taochao Tan, Zhenyu Dai, Jianfeng Zhou, Qiaoe Wei, Xiangyin Jia, Ya Zhao, Meng Xie
  • ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING TO CD70, AND APPLICATION THEREOF
    Publication number: 20230399412
    Abstract: A CD70 antibody and a chimeric antigen receptor (CAR) that can specifically bind to a CD70 protein. The CAR comprises a CD70 binding domain, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain. Further disclosed is an application of the antibody and the CAR for treating diseases or conditions related to CD70 expression.
    Type: Application
    Filed: October 12, 2021
    Publication date: December 14, 2023
    Applicant: Nanjing IASO Biotechnology Co., Ltd.
    Inventors: Yongkun Yang, Guang Hu, Panpan Niu, Guangrong Meng, Jialu Mo, Jianhua Zhang, Qianli Hu, Wei Cheng, Taochao Tan, Qiaoe Wei, Xiangyin Jia, Zhenyu Dai
  • FULLY HUMAN ANTIBODY TARGETING CD19 AND APPLICATION THEREOF
    Publication number: 20220220200
    Abstract: Provided are a fully human antibody targeting CD19 or a single chain antibody or fragment thereof. Further provided is a chimeric antigen receptor (CAR) constructed by using a single chain antibody (scFv) derived from the fully human antibody. The fully human antibody and the CAR can be used for the construction of CAR-T cells targeting CD19. Compared with CAR-T cells using murine antibodies, the CAR-T cells have better compatibility with the human body, which is beneficial to their long-term proliferation and survival in the body.
    Type: Application
    Filed: May 20, 2020
    Publication date: July 14, 2022
    Applicant: NANJING IASO BIOTHERAPEUTICS CO., LTD.
    Inventors: Taochao Tan, Zhenyu Dai, Xiangyin Jia, Qiaoe Wei, Yongkun Yang